Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Merck KGaA/Oncothyreon's Stimuvax vaccine earns Decision Resources' proprietary clinical gold standard status in 2013 and 2018 for the treatment of locally advanced non-small-cell lung cancer. Available data from Phase II clinical trials of Stimuvax have shown promising median overall survival and tumor response rates in patients when the drug is used as a maintenance therapy following chemoradiotherapy.

"Interviewed oncologists are excited about Stimuvax's Phase IIb clinical trial results in a subset of patients with locally advanced disease, and they are hopeful that the findings will be supported by positive Phase III data, especially given that ongoing studies include patients who will have a lower tumor burden than those involved in the Phase IIb trial," stated Decision Resources Analyst Janie Cox, Ph.D.

The new report entitled Locally Advanced Non-Small-Cell Lung Cancer: Targeted Agents and New Treatment Strategies Pave the Way also finds that a drug that improves median overall survival when used in conjunction with radiotherapy or chemoradiotherapy compared with etoposide (Bristol-Myers Squibb's Etopophos/Vepesid/Vepsid, Baxter's Celltop, Nippon Kayaku's Lastet)/cisplatin (Bristol-Myers Squibb's Platinol-AQ/Briplatin, Pfizer's Platosin, Nippon Kayaku's Randa, generics) plus concurrent radiotherapy for the treatment of unresectable locally advanced non-small-cell lung cancer would earn 55 percent patient share in the U.S., according to surveyed U.S. oncologists. In contrast, in Europe, such a drug would earn a lower patient share of 40 percent, according to surveyed European oncologists. Patient share of the magnitude indicated by U.S. and European oncologists would translate into healthy revenue in what is a modestly sized subpopulation of the total non-small-cell lung cancer market.

About the Report

Locally Advanced Non-Small-Cell Lung Cancer: Targeted Agents and New Treatment Strategies Pave the Way is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Christopher Comfort   Decision Resources   781-296-2597   ccomfort@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort, Decision Resources, +1-781-296-2597,
ccomfort@dresources.com

An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists

View Now